Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Alterity Therapeutics Limited

PRNAFPNK
Healthcare
Biotechnology
$0.01
$0.00(0.00%)
U.S. Market opens in 9h 43m

Alterity Therapeutics Limited Fundamental Analysis

Alterity Therapeutics Limited (PRNAF) shows moderate financial fundamentals with a PE ratio of -10.99, profit margin of -2.74%, and ROE of -38.50%. The company generates $0.0B in annual revenue with strong year-over-year growth of 35.32%.

Key Strengths

Cash Position53.73%
PEG Ratio-0.11
Current Ratio12.98

Areas of Concern

ROE-38.50%
Operating Margin-3.13%
We analyze PRNAF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -194.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-194.2/100

We analyze PRNAF's fundamental strength across five key dimensions:

Efficiency Score

Weak

PRNAF struggles to generate sufficient returns from assets.

ROA > 10%
-20.99%

Valuation Score

Excellent

PRNAF trades at attractive valuation levels.

PE < 25
-10.99
PEG Ratio < 2
-0.11

Growth Score

Excellent

PRNAF delivers strong and consistent growth momentum.

Revenue Growth > 5%
35.32%
EPS Growth > 10%
63.46%

Financial Health Score

Excellent

PRNAF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
12.98

Profitability Score

Weak

PRNAF struggles to sustain strong margins.

ROE > 15%
-3849.67%
Net Margin ≥ 15%
-2.74%
Positive Free Cash Flow
No

Key Financial Metrics

Is PRNAF Expensive or Cheap?

P/E Ratio

PRNAF trades at -10.99 times earnings. This suggests potential undervaluation.

-10.99

PEG Ratio

When adjusting for growth, PRNAF's PEG of -0.11 indicates potential undervaluation.

-0.11

Price to Book

The market values Alterity Therapeutics Limited at 2.50 times its book value. This may indicate undervaluation.

2.50

EV/EBITDA

Enterprise value stands at -16.89 times EBITDA. This is generally considered low.

-16.89

How Well Does PRNAF Make Money?

Net Profit Margin

For every $100 in sales, Alterity Therapeutics Limited keeps $-2.74 as profit after all expenses.

-2.74%

Operating Margin

Core operations generate -3.13 in profit for every $100 in revenue, before interest and taxes.

-3.13%

ROE

Management delivers $-38.50 in profit for every $100 of shareholder equity.

-38.50%

ROA

Alterity Therapeutics Limited generates $-20.99 in profit for every $100 in assets, demonstrating efficient asset deployment.

-20.99%

Following the Money - Real Cash Generation

Operating Cash Flow

Alterity Therapeutics Limited generates limited operating cash flow of $-15.55M, signaling weaker underlying cash strength.

$-15.55M

Free Cash Flow

Alterity Therapeutics Limited generates weak or negative free cash flow of $-10.76M, restricting financial flexibility.

$-10.76M

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

PRNAF converts -4.80% of its market value into free cash.

-4.80%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-10.99

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.11

vs 25 benchmark

P/B Ratio

Price to book value ratio

2.50

vs 25 benchmark

P/S Ratio

Price to sales ratio

43.77

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.004

vs 25 benchmark

Current Ratio

Current assets to current liabilities

12.98

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.38

vs 25 benchmark

ROA

Return on assets percentage

-0.21

vs 25 benchmark

ROCE

Return on capital employed

-0.26

vs 25 benchmark

How PRNAF Stacks Against Its Sector Peers

MetricPRNAF ValueSector AveragePerformance
P/E Ratio-10.9929.45 Better (Cheaper)
ROE-38.50%779.00% Weak
Net Margin-274.26%-24936.00% (disorted) Weak
Debt/Equity0.000.26 Strong (Low Leverage)
Current Ratio12.984.65 Strong Liquidity
ROA-20.99%-19344.00% (disorted) Weak

PRNAF outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Alterity Therapeutics Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

83.11%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

83.01%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ